UNR844-Cl + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia
Trial Timeline
Apr 26, 2019 → Dec 16, 2019
NCT ID
NCT03809611About UNR844-Cl + Placebo
UNR844-Cl + Placebo is a phase 2 stage product being developed by Novartis for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT03809611. Target conditions include Presbyopia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03809611 | Phase 2 | Completed |
Competing Products
14 competing products in Presbyopia